Clinical application of bedside point-of-care gene testing (gene POCT) in the rapid intraoperative molecular pathology diagnosis of IDH mutation etc. in glioma

Establishment and clinical application of the whole course accurate diagnosis and treatment technology system of glioma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100048172

Enrollment

Unknown

Registered

2021-07-04

Start date

2021-07-04

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

Gold Standard:IDH Mutations etc. Sequencing

Index test:intraoperative&#32

gene&#32

of&#32

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Preoperative diagnosis of glioma; 2. Patients requiring surgical resection and biopsy.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiopulmonary insufficiency and coagulation dysfunction and other surgical contraindications; 2. Patients who refuse genetic testing.

Design outcomes

Primary

Measure	Time frame
IDH1 R132 mutation;IDH2 R172 mutation;telomerase reverse transcriptase promoter mutation;1p/19q codeletion;TP53 mutation;CDKN2A/B mutation;BRAF mutation;MYB- or MYBL1-altered;H3 K27-altered;H3 G34-mutant;NF1 mutation;PTEN mutation;	—

Secondary

Measure	Time frame
FGFR1-TACC1 fusion;KIAA1549-BRAF fusion;	—

Countries

China

Contacts

Public ContactLi Gang

Qilu Hospital of Shandong University

dr.ligang@sdu.edu.cn+86 13606373098

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026